BioMarin's gene therapy pipeline has had setbacks, including a three-year delay in US approval of Roctavian and stalled development of PKU gene therapy BMN 307 as the Food and Drug Administration ...
BMRN reports better-than-expected fourth-quarter results, driven by encouraging uptake for Voxzogo. It reiterates its guidance of generating $4 billion in total sales by 2027.
Both of Genzyme's products are indicated for the treatment ... of their plant cell technology platform with this lead drug to perhaps provide a more cost-effective therapy,” he says, adding ...
The drug, IONIS-AZ5-2.5RX ... Developed in partnership with Sanofi's Genzyme unit, patisiran is currently under review in the US and EU. If approved Alnylam will market patisiran in the US ...
Genzyme continued to drive growth for Sanofi ... analysts predicting sales of several billion dollars a year for the drug. Sanofi said the consolidation of Bioverativ, the haemophilia specialist ...
Copyright 2025 The Associated Press. All Rights Reserved. The U.S. Food and Drug Administration campus in Silver Spring, Md., is photographed on Oct. 14, 2015. (AP ...
Drug discovery is the process through which potential new medicines are identified. It involves a wide range of scientific disciplines, including biology, chemistry and pharmacology. The field of ...
Effective drug treatment of active inflammatory rheumatic disease is possible with reasonable safety for the fetus/child during pregnancy and lactation. The dissemination of the data to health ...
After hours: February 18 at 5:17:49 PM EST Loading Chart for IGMS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback